Related Experiment Video
Updated: Mar 3, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Impact of Continuous Glucose Monitor on Health Care Resource Utilization in Adults with Type 2 Diabetes Managed by
Anup K Sharma1, Abraham Lee2, Shivani Mehta2
1Art Pharmacy, Marietta, Georgia, USA.
Background:
Daily use of continuous glucose monitoring (CGM) has been shown to reduce diabetes-related events and associated costs in individuals with type 2 diabetes (T2D) regardless of their therapy. However, adoption of CGM among the large majority of T2D adults in the United States who are treated with noninsulin therapies has been limited.
Methods:
This retrospective database study assessed the effects of CGM acquisition on health care resource utilization (HCRU) in a large cohort of T2D adults treated with noninsulin, antidiabetes therapies. Inclusion criteria were T2D diagnosis, age ≥18 years, treated with noninsulin therapies, CGM-naive before CGM acquisition, and continuous medical/pharmacy insurance coverage during the 12-month preindex and postindex periods. The primary outcome measures were changes in all-cause hospitalizations (ACH), emergency department (ED) visits, acute diabetes complications, hyperglycemic events (HGE), and diabetic ketoacidosis (DKA) during the 12 months following CGM acquisition.
Results:
A total of 20,468 adults with T2D were included in this analysis. CGM acquisition was associated with significant reductions in event rates in the postindex period compared with the preindex period HCRU at 12 months: ACH (-25%), ED visits (-7%), HGE (-7%), DKA (-86%), and acute diabetes complications (-7%), all P < 0.0001. Similar reductions in events per person were also observed: ACH (-20.6%), ED visits (-7.2%), HGE (-6.2%), DKA (-63.0%), and acute diabetes complications (-6%), all P < 0.0001. Significant reductions were also seen in patients with cardiovascular disease. ACH and ED visits decreased by 35% and 12%, respectively; in those with liver disease by 25% and 13%; in those with renal disease, ACH decreased by 33%; and in those with hypertension, ACH and ED visits decreased by 26% and 7%, respectively. All reductions were statistically significant (P < 0.01).
Conclusions:
This analysis demonstrated an association between CGM acquisition and reductions in HCRU in adults with T2D treated with noninsulin therapies.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Symptoms, Diagnosis, and Complications
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

